These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 37541935)
21. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. John AO; Ramnath N Oncologist; 2023 Sep; 28(9):752-764. PubMed ID: 37338126 [TBL] [Abstract][Full Text] [Related]
22. Top advances of the year: Perioperative therapy for lung cancer. Aredo JV; Wakelee HA Cancer; 2024 Sep; 130(17):2897-2903. PubMed ID: 38717993 [TBL] [Abstract][Full Text] [Related]
23. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Mountzios G; Remon J; Hendriks LEL; García-Campelo R; Rolfo C; Van Schil P; Forde PM; Besse B; Subbiah V; Reck M; Soria JC; Peters S Nat Rev Clin Oncol; 2023 Oct; 20(10):664-677. PubMed ID: 37488229 [TBL] [Abstract][Full Text] [Related]
24. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer]. Wang S; Mao Y Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581 [TBL] [Abstract][Full Text] [Related]
25. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges. D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413 [TBL] [Abstract][Full Text] [Related]
26. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer]. Shu C; Zhu D; Zhou Q Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. Hines JB; Cameron RB; Esposito A; Kim L; Porcu L; Nuccio A; Viscardi G; Ferrara R; Veronesi G; Forde PM; Taube J; Vokes E; Bestvina CM; Dolezal JM; Sacco M; Monteforte M; Cascone T; Garassino MC; Torri V J Thorac Oncol; 2024 Jul; 19(7):1108-1116. PubMed ID: 38461929 [TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713 [TBL] [Abstract][Full Text] [Related]
30. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001 [TBL] [Abstract][Full Text] [Related]
31. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition]. Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489 [TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Zhao Z; Gao Y; Xue Q; Gao S; He J Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556 [TBL] [Abstract][Full Text] [Related]
33. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284 [TBL] [Abstract][Full Text] [Related]
34. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer]. Qi C; Tian P; Li W Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446 [TBL] [Abstract][Full Text] [Related]
35. Current status of immune checkpoint inhibition in early-stage NSCLC. Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921 [TBL] [Abstract][Full Text] [Related]
36. [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer]. Yao S; Zhang Y Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):55-59. PubMed ID: 31948539 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives. Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393 [TBL] [Abstract][Full Text] [Related]
39. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Friedlaender A; Naidoo J; Banna GL; Metro G; Forde P; Addeo A Cancer Treat Rev; 2022 Mar; 104():102350. PubMed ID: 35093800 [TBL] [Abstract][Full Text] [Related]